Wolfe Research analyst Andy Chen initiated coverage of MoonLake Immunotherapeutics with an Outperform rating and $77 price target. The firm has a bullish view of the PsA readout in the first half of the year and expects the company to outperform in Q1.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MLTX:
